Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.03B 899M 839M 771M 1.45B 98.66B 1.48B 9.88B 3.87B 49.19B 3.89B 3.8B 163B P/E 2026 *
-14.8x
P/E 2027 * -12.3x
Enterprise Value 1.03B 899M 839M 771M 1.45B 98.66B 1.48B 9.88B 3.87B 49.19B 3.89B 3.8B 163B EV / Sales 2026 *
27.1x
EV / Sales 2027 * 51.4x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.87%
1 week+1.75%
Current month+0.87%
1 month+0.43%
3 months+42.94%
6 months+86.40%
Current year+102.61%
1 week 2.16
Extreme 2.165
2.42
1 month 2.04
Extreme 2.04
2.44
Current year 1.1
Extreme 1.1
2.68
1 year 1.02
Extreme 1.02
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 07/07/2024
Director of Finance/CFO 59 01/01/2025
Chief Tech/Sci/R&D Officer - 31/01/2025
Director TitleAgeSince
Chairman 83 31/12/2004
Chairman 71 26/02/2012
Director/Board Member 67 27/08/2007
Date Insider Type Main position Quantity % Market Cap.
28/02/26 Fiscal year

General Counsel

651,031 0.1792%
28/02/26 Fiscal year

Chief Executive Officer

1,211,357 0.3333%
28/02/26 Fiscal year

Chief Financial Officer

375,355 0.1033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%+1.75%+117.76%+23.28% 1.03B
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +1.13%-1.60%+46.72%+151.35% 23.49B
Weighted average by Cap. +0.14%-1.69%+32.09%+122.69%

Financials

2026 *2027 *
Net sales 38.17M 33.17M 30.93M 28.42M 53.61M 3.64B 54.54M 365M 143M 1.81B 143M 140M 6.01B 20.15M 17.51M 16.33M 15.01M 28.31M 1.92B 28.8M 192M 75.42M 958M 75.68M 74.02M 3.17B
Net income -66.94M -58.17M -54.24M -49.85M -94.02M -6.38B -95.65M -639M -250M -3.18B -251M -246M -10.54B -88.26M -76.7M -71.52M -65.73M -124M -8.41B -126M -843M -330M -4.19B -331M -324M -13.89B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
03/08/26 US$2.330 +0.87% 2,052,346
31/07/26 US$2.310 -1.28% 2,767,972
30/07/26 US$2.340 +0.86% 2,464,426
29/07/26 US$2.320 -0.85% 2,476,278
28/07/26 US$2.340 +4.93% 2,680,219
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.330USD
Average target price
3.770USD
Spread / Average Target
+61.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock